NovoCure (STU:038) Inventories, Finished Goods: €27.0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:038 NovoCure Ltd STU:038
74 GF Score
Price €12.89
GF Value €15.76
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is NovoCure Inventories, Finished Goods?

NovoCure STU:038 -1.79% 74 Inventories, Finished Goods is €27.0 Mil as of Jun. 2026. GuruFocus rates STU:038 with a GF Score™ of 74/100 and a GF Value™ of €15.76 (Modestly Undervalued). The stock has 4 warning signs investors should review.

NovoCure's quarterly finished goods increased from Dec. 2025 (€24.8 Mil) to Mar. 2026 (€27.5 Mil) but then declined from Mar. 2026 (€27.5 Mil) to Jun. 2026 (€27.0 Mil).

NovoCure's annual finished goods increased from Dec. 2023 (€16.6 Mil) to Dec. 2024 (€22.1 Mil) and increased from Dec. 2024 (€22.1 Mil) to Dec. 2025 (€24.8 Mil).

NovoCure Inventories, Finished Goods Historical Data

* Premium members only.

The historical data trend for NovoCure's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NovoCure Inventories, Finished Goods Chart

NovoCure Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Finished Goods
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.98 14.86 16.59 22.07 24.83

NovoCure Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28.10 25.31 24.83 27.47 27.03
STU:038
74GF Score
NovoCure Ltd STU:038
Inventories, Finished Goods is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NovoCure Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

What does a Inventories, Finished Goods of €27.0 Mil mean?
NovoCure (STU:038) has a Inventories, Finished Goods of €27.0 Mil as of Jun. 2026. Finished goods are inventory items that are complete and ready to be sold. View historical data on NovoCure and its competitors.
Is NovoCure's Inventories, Finished Goods too high?
NovoCure's current Inventories, Finished Goods is €27.0 Mil. Overall, NovoCure has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does NovoCure's Inventories, Finished Goods compare to NEOG and AXGN?
NovoCure's Inventories, Finished Goods of €27.0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Finished Goods for a Medical Devices & Instruments company?
A good Inventories, Finished Goods depends on the Medical Devices & Instruments industry context. However, Inventories, Finished Goods should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Finished Goods mean?
A high Inventories, Finished Goods can signal that a stock is expensive relative to its fundamentals. Finished goods are inventory items that are complete and ready to be sold. View historical data on NovoCure and its competitors. NovoCure's current Inventories, Finished Goods is €27.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NovoCure stock overvalued right now?
Based on GuruFocus' analysis, NovoCure (STU:038) is currently considered Modestly Undervalued. The stock's GF Value™ is €15.76, compared to a current price of €12.89 — trading 18.2% below its estimated fair value. The current Inventories, Finished Goods is €27.0 Mil. NovoCure's overall GF Score™ is 74/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Finished Goods calculated?
Inventories, Finished Goods is calculated from a company's financial statements. For NovoCure (STU:038), the current Inventories, Finished Goods is €27.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is NovoCure (STU:038) Overvalued in 2026?

Based on GuruFocus' analysis, NovoCure stock appears to be undervalued. The current stock price of €12.89 is trading 18.2% below its estimated GF Value™ of €15.76. GuruFocus considers NovoCure to be Modestly Undervalued.

Key valuation signals for STU:038:

  • Inventories, Finished Goods: €27.0 Mil
  • GF Value™: €15.76 vs. price of €12.89 (18.2% below fair value)
  • GF Score™: 74/100 with 4 warning signs

No single metric tells the full story. See the STU:038 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

NovoCure Business Description

Address Grenville Street, No. 4 The Forum, Second Floor, St. Helier, JEY, JE2 4UF
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.
74GF Score

Get the complete analysis for STU:038

Inventories, Finished Goods is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€12.89
Price
€15.76
GF Value